EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease

Joanna Żukowska, Stephen J Moss, Vasanta Subramanian, K Ravi Acharya iD

The FEBS Journal · 2024-07 · 291 (14) · 2999-3029

DOI: 10.1111/febs.16939 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 08.09.2023. Verfasst von Joanna Żukowska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Society (UK), University of Kentucky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The accumulation of the small 42‐residue long peptide amyloid‐β (Aβ) has been proposed as a major trigger for the development of Alzheimer's disease (AD). Within the brain, the concentration of Aβ peptide is tightly controlled through production and clearance mechanisms. Substantial experimental evidence now shows that reduced levels of Aβ clearance are present in individuals living with AD. This accumulation of Aβ can lead to the formation of large aggregated amyloid plaques—one of two detectable hallmarks of the disease. Aβ‐degrading enzymes (ADEs) are major players in the clearance of Aβ. Stimulating ADE activity or expression, in order to compensate for the decreased clearance in the AD phenotype, provides a promising therapeutic target. It has been reported in mice that upregulation of ADEs can reduce the levels of Aβ peptide and amyloid plaques—in some cases, this led to improved cognitive function. Among several known ADEs, neprilysin (NEP), endothelin‐converting enzyme‐1 (ECE‐1), insulin degrading enzyme (IDE) and angiotensin‐1 converting enzyme (ACE) from the zinc metalloprotease family have been identified as important. These ADEs have the capacity to digest soluble Aβ which, in turn, cannot form the toxic oligomeric species. While they are known for their amyloid degradation, they exhibit complexity through promiscuous nature and a broad range of substrates that they can degrade. This review highlights current structural and functional understanding of these key ADEs, giving some insight into the molecular interactions that leads to the hydrolysis of peptide substrates, the crucial tasks performed by them and the potential for therapeutic use in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesHumansAnimalsNeprilysinInsulysinProteolysis

Stichwörter der Autor:innen

Alzheimer's diseaseAmyloid‐degrading enzymeAβ‐peptidemolecular structuretherapeutic use

Substanzen

Amyloid beta-PeptidesNeprilysinInsulysin

Autor:innen und Institutionen

  • Department of Life Sciences, University of Bath, UK.

ORCID-Profile: K Ravi Acharya

Förderung

  • Alzheimer's Society (UK)
  • University of Kentucky

Zitieren

APA

Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2024). Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease. The FEBS Journal, 291(14), 2999-3029. https://doi.org/10.1111/febs.16939

Vancouver

Żukowska J, Moss SJ, Subramanian V, Acharya KR. Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease. The FEBS Journal. 2024;291(14):2999-3029. doi:10.1111/febs.16939

BibTeX
@article{ukowska2024,
  author = {Żukowska, Joanna and Moss, Stephen J and Subramanian, Vasanta and Acharya, K Ravi},
  title = {Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease},
  journal = {The FEBS Journal},
  year = {2024},
  volume = {291},
  number = {14},
  pages = {2999--3029},
  doi = {10.1111/febs.16939}
}
Kostenlos starten →